Dexcom Inc
NASDAQ:DXCM
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
P/OCF
Price to Operating Cash Flow (P/OCF) ratio compares a company`s market value to the cash it generates from its core operations.
Price to Operating Cash Flow (P/OCF) ratio compares a company`s market value to the cash it generates from its core operations.
Valuation Scenarios
If P/OCF returns to its 3-Year Average (34.9), the stock would be worth $131.35 (114% upside from current price).
| Scenario | P/OCF Value | Implied Price | Upside/Downside |
|---|---|---|---|
| Current Multiple | 16.3 | $61.41 |
0%
|
| 3-Year Average | 34.9 | $131.35 |
+114%
|
| 5-Year Average | 59.7 | $224.83 |
+266%
|
| Industry Average | 16.1 | $60.48 |
-2%
|
| Country Average | 13.3 | $50.21 |
-18%
|
Forward P/OCF
Today’s price vs future operating cash flow
Peer Comparison
| Market Cap | P/OCF | P/E | ||||
|---|---|---|---|---|---|---|
| US |
|
Dexcom Inc
NASDAQ:DXCM
|
23.6B USD | 16.3 | 28.1 | |
| US |
|
Intuitive Surgical Inc
NASDAQ:ISRG
|
167.2B USD | 55.2 | 58.6 | |
| US |
|
Abbott Laboratories
NYSE:ABT
|
161.2B USD | 16.8 | 25.7 | |
| US |
|
Stryker Corp
NYSE:SYK
|
125.8B USD | 24.9 | 38.8 | |
| IE |
|
Medtronic PLC
NYSE:MDT
|
106.4B USD | 14.6 | 23.1 | |
| US |
|
Boston Scientific Corp
NYSE:BSX
|
88.9B USD | 19.6 | 24.9 | |
| US |
|
Edwards Lifesciences Corp
NYSE:EW
|
48.5B USD | 30.4 | 44.2 | |
| DE |
|
Siemens Healthineers AG
XETRA:SHL
|
40.1B EUR | 13.2 | 18.9 | |
| US |
|
IDEXX Laboratories Inc
NASDAQ:IDXX
|
45.8B USD | 38.8 | 43.3 | |
| US |
|
Becton Dickinson and Co
NYSE:BDX
|
42.8B USD | 12.6 | 24.3 | |
| US |
|
Resmed Inc
NYSE:RMD
|
32.3B USD | 16.9 | 21.8 |
Market Distribution
| Min | 0 |
| 30th Percentile | 8.8 |
| Median | 13.3 |
| 70th Percentile | 20.1 |
| Max | 3 188 432.5 |
Other Multiples
Dexcom Inc
Glance View
Dexcom Inc. emerged as a pioneering force in the realm of continuous glucose monitoring (CGM), redefining the landscape of diabetes management. Founded in 1999, this San Diego-based company disrupted traditional blood glucose monitoring with its innovative technology, allowing individuals to track glucose levels in real-time without frequent finger-pricking. The company’s CGM systems, such as the G6 model, utilize a small sensor inserted beneath the skin that transmits data to a wearable device or smartphone, allowing patients and healthcare providers a comprehensive view of glucose trends. This approach empowers users with critical information for better diabetes management, reducing the likelihood of complications resulting from high or low blood sugar. Dexcom’s revenue generation revolves around the sales of its CGM systems, sensors, and related software services. By selling the initial monitoring devices and disposable sensors that typically need to be replaced every ten days, the company ensures a steady, recurring revenue stream. Furthermore, its integration with healthcare providers and insurers broadens its reach, tapping into a vast network of patients worldwide. Dexcom also collaborates with tech giants to enhance interoperability and data analytics, thereby embedding its solutions in broader digital health ecosystems. As diabetes continues to be a growing global concern, Dexcom’s strategic focus on innovation and strategic partnerships positions it as a leader in the CGM market.